Genome Engineering Market Headed for Growth and Global Expansion by 2026 With Top Players Thermo Fisher Scientific Inc., CRISPR Therapeutics AG, Intellia Therapeutics, Inc., Editas Medicine, Inc

Genome engineering is a technique in which a DNA is inserted, deleted, modified or replaced in the genome of a living organism. Research and development activities are conducted in genome engineering for the development of novel technologies. For instance, in 2017, Synthego Corporation launched a CRISPR Pioneers Program to expand genome engineering research. Researchers are majorly focusing on developing treatments for cancer and rare diseases with the help of genome engineering tools such as CRISPER. Many genome technologies are under trial for treatment of such diseases, and are expected to receive approvals in the near future.

Market Dynamics

Development of novel technologies in genome engineering field is expected to significantly drive growth of the global genome engineering market in the near future. For instance, in 2017, Merck KGaA— Germany-based company—developed a new genome editing tool dubbed 'proxy-CRISPR', providing access to previously inaccessible microenvironments of the genome by modification of chromatin modifications. In 2017, Benson Hill Biosystems, Inc.—an agricultural technology company—launched its latest CRISPR 3.0, to increase innovators’ access to gene editing. CRISPR 3.0 is a latest innovative genomics tool, which is expected to improve crop performance. Development of such novel technologies by major key players is expected to create a conducive environment for growth of market. The global genome engineering market was valued at US$ 2,582.7 Mn in 2016 and is expected to witness a CAGR of 14.3% over the forecast period (2017–2025).

Request Our Highly Informative Sample Copy of This Business Report : https://www.coherentmarketinsights.com/insight/request-sample/1262

Increasing development of novel technologies in genome engineering is expected to drive growth of the global genome engineering market in the near future

Key players in the market are focusing on developing novel technologies and launching new products for genome engineering, in order to increase their market share. For instance, in February 2018, Sangamo Therapeutics, Inc. received clinical trial authorization (CTA) from Medicines and Healthcare Products Regulatory Agency (MHRA) in the U.K. for its SB-FIX, a zinc finger nuclease (ZFN)-mediated in-vivo genome editing treatment for hemophilia B. CTA has allowed for the beginning of Europe's first in-vivo genome editing study. In 2017, Integrated DNA Technologies, Inc. launched the first Cas9 enzyme variant, which reduces off-target effects in CRISPR genome editing. The launch of latest Cas9 enzyme variant is a major step towards therapeutic use of CRISPR.

In 2017, Scientists at Salk Institute for Biological Studies, modified CRISPR to epigenetically treat diabetes, kidney disease, and muscular dystrophy. They developed a latest version of CRISPR/Cas9 genome editing technology, which allows for activation of genes without creating breaks in the DNA. The development of such novel technologies is expected to be major driving factor for growth of global genome engineering market.

Increasing strategic collaboration for genome engineering technologies by key players is expected to drive market growth in the near future

Players in the market are focusing on strategic collaborations, in order to increase their product offerings. For instance, in February 2018, Kite Pharma, Inc.—a Gilead Sciences, Inc. company— collaborated with Sangamo Therapeutics Inc. for developing engineered cell therapies to treat cancer. As per the agreement, Kite Pharma, Inc. will use Sangamo Therapeutics’ zinc finger nuclease (ZFN) gene-editing technology for developing next-generation ex vivo cell therapies for treatment of cancer. Furthermore, in 2017, Synthego and Thermo Fisher Scientific collaborated to manufacture and distribute synthetic guide RNA products for CRISPR genome engineering. In 2016, CRISPR Therapeutics and Bayer AG collaborated and formed a joint venture Casebia Therapeutics, for developing CRISPR-based therapeutics in select disease areas.

Moreover, in 2017, Casebia Therapeutics collaborated with CureVac AG. According to collaboration agreement, CureVac will develop novel Cas9 mRNA constructs with improved properties for gene editing applications. In 2015, AstraZeneca plc. announced research collaborations with The Wellcome Trust Sanger Institute, The Innovative Genomics Initiative, Thermo Fisher Scientific, and Broad Institute/Whitehead Institute to use their CRISPR technology for genome editing. Such strategic collaborations among major key players and research institutes is expected to drive market growth in the near future.

Request Customization : https://www.coherentmarketinsights.com/insight/request-customization/1262

Competitive Landscape

Key players operating in the genome engineering market include Thermo Fisher Scientific Inc., CRISPR Therapeutics AG, Intellia Therapeutics, Inc., Editas Medicine, Inc., Sangamo Therapeutics, Inc., Bluebird Bio, Inc., Cellectis S.A., and Merck Group.

Increasing funding and investments for the development and research of new genetic engineering technologies is also expected to drive market growth. For instance, in January 2018, the U.S. National Institutes of Health (NIH) announced to grant US$ 190 million for genome editing research. This new program, Somatic Cell Genome Editing, will award funds to biomedical researchers over the following six years. The support from major research organizations such as NIH is expected to attract more researchers in this field, which may lead to advancements in technology and also aid in growth of the market.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

This release was published on openPR.